Immunotherapy advances最新文献

筛选
英文 中文
Combination of proton-pump inhibitor and anti-CD3 F(ab')2 for islet neogenesis and immune modulation in type 1 diabetes. 质子泵抑制剂和抗cd3f (ab')2联合用于1型糖尿病胰岛新生和免疫调节。
IF 4.4
Immunotherapy advances Pub Date : 2026-07-22 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag017
Tung-Yun Wu, Che-Yi Chen, Michael Chen, Chang-Hung Wang, An-Pei Kao, Kai-Hung Wang, Kuo-Hsiang Chuang, Shyr-Yi Lin
{"title":"Combination of proton-pump inhibitor and anti-CD3 F(ab')<sub>2</sub> for islet neogenesis and immune modulation in type 1 diabetes.","authors":"Tung-Yun Wu, Che-Yi Chen, Michael Chen, Chang-Hung Wang, An-Pei Kao, Kai-Hung Wang, Kuo-Hsiang Chuang, Shyr-Yi Lin","doi":"10.1093/immadv/ltag017","DOIUrl":"10.1093/immadv/ltag017","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell-mediated destruction of pancreatic β cells. Current insulin therapy does not address autoimmune pathology or restore endogenous β-cell function, highlighting the need for disease-modifying strategies.</p><p><strong>Methods: </strong>We developed a combination therapy integrating a proton pump inhibitor (PPI; omeprazole) with a non-Fc-binding anti-CD3 F(ab')<sub>2</sub> antibody fragment (anti-CD3 F(ab')<sub>2</sub>) to concurrently promote β-cell neogenesis and modulate autoimmune T-cell responses. T1D was induced in nonobese diabetic (NOD) mice using a cyclophosphamide-accelerated protocol (CY-NOD). Following hyperglycemia onset, mice received combination treatment and were evaluated by blood glucose monitoring, flow cytometric analysis of T-cell populations, and assessment of pancreatic β-cell function. Therapeutic efficacy was further examined in spontaneous-onset NOD mice.</p><p><strong>Results: </strong>Combination therapy restored normoglycemia without exogenous insulin, reduced lymphocytic infiltration in pancreatic islets, and preserved endogenous insulin secretion. Treatment decreased pathogenic CD4<sup>+</sup> and CD8<sup>+</sup> T cells, increased regulatory T cells, and enhanced transforming growth factor-β expression. Comparable and durable glycemic control was observed in spontaneous-onset NOD mice.</p><p><strong>Conclusions: </strong>Concurrent modulation of β-cell function and autoimmune immunity achieved sustained glycemic control in T1D models. The use of clinically approved agents supports the translational potential of this non-insulin-dependent therapeutic strategy.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag017"},"PeriodicalIF":4.4,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148654831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. 生长因子支持治疗化疗诱导的中性粒细胞减少症抑制检查点阻断反应性胰腺癌的抗肿瘤免疫。
IF 4.4
Immunotherapy advances Pub Date : 2026-07-15 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag013
Brendan D Parent, Anthony E Kelly, Megan T Hoffman, Michael Dougan, Andrew J Aguirre, Stephanie K Dougan
{"title":"Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer.","authors":"Brendan D Parent, Anthony E Kelly, Megan T Hoffman, Michael Dougan, Andrew J Aguirre, Stephanie K Dougan","doi":"10.1093/immadv/ltag013","DOIUrl":"10.1093/immadv/ltag013","url":null,"abstract":"<p><strong>Introduction: </strong>Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treatment of chemotherapy-induced neutropenia, yet their effects on antitumour immunity remain incompletely understood. We previously found that serum from patients with pancreatic ductal adenocarcinoma (PDAC) treated with multiagent chemotherapy plus G-CSF drove differentiation of T cell-suppressive monocytes <i>in vitro</i>, suggesting that supportive care interventions may shape immune responses in this disease.</p><p><strong>Methods: </strong>We evaluated the immunologic and therapeutic impact of G-CSF in two murine PDAC models that differ in their baseline frequencies of infiltrating T cells and in their responsiveness to checkpoint blockade immunotherapy.</p><p><strong>Results: </strong>In poorly immunogenic, T-cell-low tumours, use of G-CSF did not affect tumour growth or response to chemo- or immunotherapy, although neutrophil recovery was improved in mice receiving FOLFIRINOX and G-CSF compared to chemotherapy alone. In immunogenic tumours with a robust endogenous T-cell response, combination anti-PD1 and anti-CTLA-4 therapy resulted in durable tumour clearance. Combination with G-CSF diminished the effectiveness of checkpoint blockade and resulted in significantly fewer cured mice.</p><p><strong>Conclusion: </strong>G-CSF, commonly used for supportive care with FOLFIRINOX and other chemotherapy regimens, induces systemic immune suppression that can reduce the efficacy of T-cell-targeting immunotherapies.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag013"},"PeriodicalIF":4.4,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13398997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148586175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular immunotherapy for acute myeloid leukemia: from bench to bedside. 细胞免疫治疗急性髓性白血病:从实验到临床。
IF 4.4
Immunotherapy advances Pub Date : 2026-07-08 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag012
Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao
{"title":"Cellular immunotherapy for acute myeloid leukemia: from bench to bedside.","authors":"Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao","doi":"10.1093/immadv/ltag012","DOIUrl":"https://doi.org/10.1093/immadv/ltag012","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a clonal malignant disease that arises from hematopoietic stem cells and is characterized by high genetic heterogeneity. AML has a poor prognosis, with a low 5-year survival rate, and is typically treated with chemotherapy. The management of AML, particularly for cases that are relapsed or refractory to conventional chemotherapy and transplantation, remains a formidable clinical challenge. This comprehensive review systematically evaluates the current landscape of cellular immunotherapeutic strategies for AML. We focus on the mechanisms of action, recent clinical progress, and persistent challenges associated with a range of adoptive cell therapies. These include natural killer cell-based infusions, and engineered approaches such as chimeric antigen receptor-T, CAR-NK, and CAR-macrophage therapies. Furthermore, we examine the roles of tumor-infiltrating lymphocytes and cytokine-induced killer cells. Our analysis synthesizes evidence from preclinical studies and clinical trials to assess the potential of these modalities in inducing durable antileukemic responses. We conclude that while cellular immunotherapies represent a transformative frontier in AML treatment, their broad application is currently constrained by target antigen heterogeneity, a complex tumor microenvironment, and significant toxicities. Finally, this review discusses strategic innovations necessary to overcome these barriers, highlighting directions for future research aimed at enhancing the efficacy and safety of these promising treatments for AML patients.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag012"},"PeriodicalIF":4.4,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting. 利用调节性B细胞的双重性:从特征分子的识别到治疗靶向。
IF 4.4
Immunotherapy advances Pub Date : 2026-06-26 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag011
Luman Wang, Ronghua Liu, Yiwei Chu
{"title":"Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting.","authors":"Luman Wang, Ronghua Liu, Yiwei Chu","doi":"10.1093/immadv/ltag011","DOIUrl":"10.1093/immadv/ltag011","url":null,"abstract":"<p><p>The field of immunology is increasingly intersecting with molecular biology, metabolic biology, and neurobiology (Zhu et al, A neuroimmune circuit mediates cancer cachexia-associated apathy. <i>Science</i> 2025;388:eadm8857; Jaschke et al, Gut-to-brain signaling restricts dietary protein intake during recovery from catabolic states. <i>Cell</i> 2025;188:7481-7494.e16; Zheremyan et al, Regulatory B cells: changing the landscape of immunoregulation and immunotherapy. <i>Cytokine Growth Factor Rev</i> 2025;86:121-36), marking a shift beyond traditional research approaches toward a more comprehensive understanding of the immune system. Central to this integrated perspective is the growing recognition that B cells are not only antibody producers, but also multifunctional cells dynamically modulated by their microenvironment. This comprehensive synthesis of recent research illuminates the dual nature of regulatory B cells (Bregs) as pivotal orchestrators of immune homeostasis. We examine how Bregs, governed by complex metabolic cues, neural signaling pathways, and local tissue microenvironments, can either suppress pathological inflammation or be co-opted to drive disease progression in autoimmunity, cancer, and allergic conditions. Understanding these microenvironmental determinants of Breg function is particularly critical for developing next-generation prognostic tools and targeted therapeutic strategies that effectively modulate B cell activity in various disease states.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag011"},"PeriodicalIF":4.4,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13334098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccination against tumour endothelial marker Robo4 inhibits tumour growth. 针对肿瘤内皮标记物Robo4的疫苗可抑制肿瘤生长。
IF 4.4
Immunotherapy advances Pub Date : 2026-06-25 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag005
Fernanda Escobar-Riquelme, Muhammet Ali Kara, Michael J Price, Angela Hidalgo-Gajardo, Hayley L Carr, David Bending, Roy Bicknell, Natalia Savelyeva, Kai-Michael Toellner, Yang Zhang
{"title":"Vaccination against tumour endothelial marker Robo4 inhibits tumour growth.","authors":"Fernanda Escobar-Riquelme, Muhammet Ali Kara, Michael J Price, Angela Hidalgo-Gajardo, Hayley L Carr, David Bending, Roy Bicknell, Natalia Savelyeva, Kai-Michael Toellner, Yang Zhang","doi":"10.1093/immadv/ltag005","DOIUrl":"10.1093/immadv/ltag005","url":null,"abstract":"<p><strong>Introduction: </strong>Targeting tumour antigens is a major challenge in cancer-immunotherapy. We use active vaccination to induce antibodies targeting self-antigen Robo4, which is selectively expressed on tumour vascular endothelium, and supports vascular development. Our previous work showed that a conjugate of Robo4 with a foreign carrier protein induced autoantibodies specific to Robo4, which inhibited angiogenesis and tumour growth.</p><p><strong>Methods: </strong>To translate the vaccine protocol to exploit a carrier protein used in routine human vaccination schedules, the well-characterized, non-toxic fragment C of tetanus toxin (TTc) was selected as the carrier protein. Recombinant protein Robo4-TTc (R4-TTc) was produced by Robo4 genetically linked to TTc.</p><p><strong>Results: </strong>Priming with the carrier TTc followed by boost with Robo4-TTc (R4-TTc) efficiently induces strong antibody responses to Robo4 and inhibits tumour growth in LLC1 and 4T1 tumour models. The growth inhibition was correlated with anti-Robo4 IgG1 titres. Furthermore, decreased vessel formation and increased immune cell infiltration in tumours from R4-TTc vaccinated mice in the absence of detectable adverse effects on health.</p><p><strong>Conclusion: </strong>The data indicate that this vaccination strategy remodels tumour vessels and probably promotes immunogenic pathway activation, therefore repressing tumour growth.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag005"},"PeriodicalIF":4.4,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13296997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimized procurement of cancer-reactive T-cell receptors from clinical samples. 从临床样品中优化获取癌症反应性t细胞受体。
IF 4.4
Immunotherapy advances Pub Date : 2026-06-22 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag009
Marine E Caillaud, Cristina Rius, Théo Morin, Li Rong Tan, Hannah L Thomas, Amber Rogers, Joshua Hick, Morten Nielsen, Md Samiul Hasan, Inge Marie Svane, Barbara Szomolay, Andrew K Sewell, Garry Dolton
{"title":"Optimized procurement of cancer-reactive T-cell receptors from clinical samples.","authors":"Marine E Caillaud, Cristina Rius, Théo Morin, Li Rong Tan, Hannah L Thomas, Amber Rogers, Joshua Hick, Morten Nielsen, Md Samiul Hasan, Inge Marie Svane, Barbara Szomolay, Andrew K Sewell, Garry Dolton","doi":"10.1093/immadv/ltag009","DOIUrl":"https://doi.org/10.1093/immadv/ltag009","url":null,"abstract":"<p><p>T-cell receptors can sense cancer-associated changes in cellular proteins, lipids, metabolites, and stress pathways, enabling immune-mediated tumour elimination in some patients. These receptors underpin T-cell receptor-based immunotherapies, yet their isolation from clinical samples remains challenging due to labour-intensive workflows, dependence on prior antigen knowledge, and loss of cell viability. We developed an optimized flow cytometry-based assay, termed the T107 assay, to isolate viable cancer-reactive T-cells directly from clinical samples. Following short-term exposure to cancer cells, responding T-cells are identified by simultaneous surface detection of tumour necrosis factor and the degranulation marker CD107a, enabling recovery of live antigen-reactive cells for downstream analysis. The T107 assay enabled rapid identification of cancer-reactive T-cells from tumour-infiltrating lymphocyte products derived from melanoma and sarcoma patients. The assay supported phenotypic and functional characterization of αβ and γδ T-cell receptor populations, including CD4<sup>+</sup> and CD8<sup>+</sup> subsets, responding to both patient-specific and shared cancer antigens. Isolation of viable responding cells enabled high-resolution receptor sequencing, generation of functional T-cell clones, determination of antigen specificity and major histocompatibility complex restriction or independence. Paired receptors were engineered into primary T-cells to generate T-cell receptor-engineered products capable of recognizing multiple cancer types. The T107 assay provides a rapid and robust method for antigen-agnostic procurement of viable cancer-reactive T-cells and their receptors from clinical material. This approach removes key bottlenecks in T-cell receptor discovery and is expected to accelerate development of T-cell receptor-based immunotherapies across a broad range of cancers.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag009"},"PeriodicalIF":4.4,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148802517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NLRC5 expression within tumor cells is critical to activate adaptive and innate antitumor immune responses. NLRC5在肿瘤细胞中的表达对于激活适应性和先天抗肿瘤免疫应答至关重要。
IF 4.4
Immunotherapy advances Pub Date : 2026-06-02 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag010
Akhil Shukla, Mohammad Moradzad, Akouavi Julite Irmine Quenum, Jean-François Lucier, Anny Armas Cayarga, Dominique Lévesque, François-Michel Boisvert, Thomas A Kufer, Sheela Ramanathan, Subburaj Ilangumaran
{"title":"NLRC5 expression within tumor cells is critical to activate adaptive and innate antitumor immune responses.","authors":"Akhil Shukla, Mohammad Moradzad, Akouavi Julite Irmine Quenum, Jean-François Lucier, Anny Armas Cayarga, Dominique Lévesque, François-Michel Boisvert, Thomas A Kufer, Sheela Ramanathan, Subburaj Ilangumaran","doi":"10.1093/immadv/ltag010","DOIUrl":"10.1093/immadv/ltag010","url":null,"abstract":"<p><strong>Introduction: </strong>Tumors downregulate NLRC5 expression to reduce MHC-I and evade CD8<sup>+</sup> T cell-mediated killing. Introducing full-length NLRC5 (N5FL) or NLRC5-CIITA chimeric protein (N5CA) can restore tumor immunogenicity. Here, we elucidated the underlying mechanisms and also evaluated the requirement of NLRC5 expression in antigen-presenting cells (APCs) of the host for tumor control.</p><p><strong>Materials and methods: </strong><i>Nlrc5<sup>-/-</sup></i> and <i>Nlrc5<sup>+/+</sup></i> mice were implanted with B16-F10 melanoma expressing N5FL or NC5A. Tumor growth, activation of lymphoid cells, their infiltration into tumors and the requirement for tumor control were assessed. The proteomes of B16-F10 cells expressing N5FL or N5CA were analyzed.</p><p><strong>Results: </strong>NLRC5-expressing tumors were efficiently controlled in both <i>Nlrc5<sup>+/+</sup></i> and <i>Nlrc5<sup>-/-</sup></i> mice, characterized by infiltration of CD8<sup>+</sup> and CD4<sup>+</sup> cells, natural killer (NK) cells, NK T (NKT) cells and invariant NKT (iNKT) cells, increased tumor vascularization and upregulation of <i>Ccl4</i> and <i>Cxcl9</i> genes. Both CD8<sup>+</sup> and NK1.1<sup>+</sup> cells contribute to NLRC5-dependent tumor control. NLRC5 expression in the Tumor Cancer Genome Atlas-skin cutaneous melanoma correlated with NK cell markers and nonclassical MHC-Ib expression. Proteomes of NLRC5-expressing tumor cells showed downmodulation of dominant tumor antigens, but displayed significant changes in the lysosome and the proteasome pathways, upregulated the protein processing in endoplasmic reticulum pathway, and downregulated the autophagy pathway, all of which could impact processing and presentation of subdominant tumor antigens.</p><p><strong>Conclusion: </strong>NLRC5 expression in APCs is dispensable for NLRC5-dependent antitumor immunity. NLRC5-dependent tumor control requires both CD8<sup>+</sup> and NK1.1<sup>+</sup> cells. Tumor-intrinsic NLRC5 promotes vasculature that is permissive to infiltration by antitumor immune cells. In addition to upregulating MHC-I, NLRC5 may enhance alternative antigen-processing pathways and attenuate autophagic degradation of MHC-I, thereby augmenting tumor immunogenicity.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag010"},"PeriodicalIF":4.4,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular adenosine released by mesenchymal stromal cells from young hosts boosts the antimicrobial activity of neutrophils from aged hosts against Streptococcus pneumoniae. 年轻宿主间充质基质细胞释放的胞外腺苷可增强老年宿主中性粒细胞对肺炎链球菌的抗菌活性。
IF 4.4
Immunotherapy advances Pub Date : 2026-05-14 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag007
Rania Hassan Mohamed, Michael C Battaglia, Elsa N Bou Ghanem
{"title":"Extracellular adenosine released by mesenchymal stromal cells from young hosts boosts the antimicrobial activity of neutrophils from aged hosts against <i>Streptococcus pneumoniae</i>.","authors":"Rania Hassan Mohamed, Michael C Battaglia, Elsa N Bou Ghanem","doi":"10.1093/immadv/ltag007","DOIUrl":"10.1093/immadv/ltag007","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSC) represent a potential target to reverse inflammaging and to halt immunosenescence, as these cells can modulate immune cell responses. Neutrophils, known as polymorphonuclear leukocytes (PMNs), are required for host defence against bacterial pathogens such as <i>Streptococcus pneumoniae</i>; however, their function significantly declines with age. Whether MSCs can reverse the age-driven decline in PMN antibacterial function is unknown. To test that, we cultured MSCs from young and aged mice and tested the paracrine effect of factors present in the conditioned media (CM) on antimicrobial responses of PMNs across host age. The <i>ex vivo</i> treatment with MSCs-CM from aged mice blunted the antimicrobial activity of PMNs from young hosts. However, treatment of PMNs from aged mice with young MSCs-CM significantly increased <i>S. pneumoniae</i> uptake, production of mitochondrial reactive oxygen species, and boosted overall bacterial killing. In exploring the pathways involved, we found that presence of immune modulatory extracellular adenosine in the young MSCs-CM was required for boosting PMN responses. Further, in contrast to aged mice MSCs-CM, young mice MSCs CM increased the responsiveness of aged mice PMNs to adenosine activation by upregulating the A1 adenosine receptor expression. Blocking this high affinity adenosine receptor reversed the rejuvenating effect of young mice MSCs-CM on bacterial killing by PMNs from aged hosts. In summary, this study suggests a potential cell-free therapeutic role of the young host MSC secretome in reversing the age-driven defects in PMN function against bacterial infection. It is the first study to demonstrate an anti-immunosenescence activity of the MSC secretome through extracellular adenosine.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag007"},"PeriodicalIF":4.4,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The resilient subset: cancer stem cells at the core of immunotherapy resistance. 弹性子集:癌症干细胞在免疫治疗抵抗的核心。
IF 4.4
Immunotherapy advances Pub Date : 2026-05-06 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag006
Julián A Gajón, Diego Esperante, Nahuel Ko, Aaron Jimenez-Miranda, Samira Muñoz-Cruz, Ezequiel Fuentes-Panana, Laura C Bonifaz
{"title":"The resilient subset: cancer stem cells at the core of immunotherapy resistance.","authors":"Julián A Gajón, Diego Esperante, Nahuel Ko, Aaron Jimenez-Miranda, Samira Muñoz-Cruz, Ezequiel Fuentes-Panana, Laura C Bonifaz","doi":"10.1093/immadv/ltag006","DOIUrl":"10.1093/immadv/ltag006","url":null,"abstract":"<p><p>Cancer stem cells (CSCs) are a small subset of cells that possess unique characteristics, including the ability to initiate and sustain tumor growth, self-renew, and differentiate into various types of cancer cells. They play a crucial role in tumor progression, metastasis, and recurrence. In recent years, CSCs have garnered significant attention due to their involvement in therapeutic resistance to both conventional and novel cancer treatments, including immunotherapy. This review delves into the fundamental properties of CSCs, molecular, cellular, and metabolic, focusing particularly on their immunomodulatory effects. We propose a comprehensive model that reflects the involvement of CSCs in various interlinked contexts, including key signaling pathways, the suppressive microenvironment, and the surrounding stromal components. Through this triaxial conceptualization, we highlight the key role of the stemness-orchestrated architecture in contributing to therapeutic failure. We present evidence gathered from diverse clinical settings, demonstrating a tight correlation between a stem tumor phenotype and poor clinical outcomes, including reduced survival rates and dampened response to immune checkpoint inhibitors (ICB). Finally, we propose therapeutic interventions specifically designed to disrupt the architecture of cancer stemness. These include vaccination against CSC antigens, differentiation therapies, cellular therapies, and combinatorial approaches. In summary, this review apprises an integral, up-to-date perspective that redefines the role of CSCs, positioning them at the core of immunotherapeutic resistance.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag006"},"PeriodicalIF":4.4,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13186324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147984710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease. 透明质酸酶促进10%皮下免疫球蛋白在小儿原发性免疫缺陷疾病患者中的药代动力学
IF 4.4
Immunotherapy advances Pub Date : 2026-04-03 eCollection Date: 2026-01-01 DOI: 10.1093/immadv/ltag003
Zhaoyang Li, Yang Teng, Sharon Russo-Schwarzbaum, Barbara McCoy
{"title":"Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease.","authors":"Zhaoyang Li, Yang Teng, Sharon Russo-Schwarzbaum, Barbara McCoy","doi":"10.1093/immadv/ltag003","DOIUrl":"10.1093/immadv/ltag003","url":null,"abstract":"<p><strong>Introduction: </strong>Hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is a unique and effective treatment for primary immunodeficiency disease (PID), allowing for less frequent administration than conventional subcutaneous immunoglobulin therapies.</p><p><strong>Methods: </strong>The pharmacokinetics (PK) of fSCIG 10% in pediatric patients (aged 2 to <16 years at screening) with PID was assessed in a prospective, phase 3, open-label, multicenter, clinical trial conducted in the USA. Patients previously treated with intravenous or conventional subcutaneous immunoglobulin therapy (consistent dose for ≥3 months) received fSCIG 10% via a dose ramp-up schedule for ≤6 weeks (Epoch 1), then at full target dose every 3-4 weeks for ≤3 years (Epoch 2). Serum total immunoglobulin G (IgG) trough levels were reported throughout Epoch 2 across pediatric age groups (2 to <6, 6 to <12, and 12 to ≤16 years); serial PK were characterized at the Month 6 infusion. In total, 44 patients (mean age: 9.0 years; 59% male and 91% White) were eligible for the study.</p><p><strong>Results: </strong>Mean total IgG trough levels during Epoch 2 were similar across age groups. Geometric mean area under the IgG concentration-time curve per week ranged from 63.4 to 76.8 g·day/L, and body weight-adjusted apparent clearance ranged from 1.5 to 1.9 ml/day/kg.</p><p><strong>Conclusion: </strong>This study showed that serum total IgG trough levels were effectively maintained in pediatric patients with PID treated with fSCIG 10%, regardless of age. The dosing strategy for pediatric patients should be informed by assessing individual IgG levels and clinical status as for adults.</p><p><strong>Clinical trials registration: </strong>The study is registered with the ClinicalTrials.gov registry at https://clinicaltrials.gov/ct2/study/NCT03277313 (ClinicalTrials.gov Identifier: NCT03277313).</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag003"},"PeriodicalIF":4.4,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13049483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147625079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书